Other relevant interactions have also been described; for example, relative to the use of glucocorticoids as anti-inflammatory therapy during COVID-19; and also via the synthesis of lipid mediators, such as overexpression of the 2-arachidonoylglycerol or underexpression of the platelet-activating factor (PAF) induced by modification of lipid metabolism-enzyme gene expression37. This evidence concerns the gene PCLAF and COVID-19.